Joint Symposium 24
Thyroid + Oncology & Theranostics Committee / European Society for Medical Oncology (ESMO)
Accessible on-demand at any time

Session Title
Theranostics in Thyroid Cancer Beyond Radioactive Iodine

Chairperson
Désirée Deandreis (Turin, Italy)

Programme
25 min Sophie Leboulleux (Villejuif, France / ESMO): Molecular Basis of Differentiated Thyroid Cancer
20 min Calogero D’Alessandria (Munich, Germany): New Targets for Thyroid Cancer in Pre-Clinical Research
20 min Martina Sollini (Milan, Italy): PSMA in Thyroid Cancer
22 min Désirée Deandreis (Turin, Italy): PRRT and Alpha Emitters in Thyroid Cancer
3 min Session Summary by Chairperson

Educational Objectives
1. Molecular basis of differentiated thyroid cancer
2. Insights in the identification and development of new radiopharmaceuticals in pre-clinical research
3. Evidence and Perspectives in the use of radiopharmaceuticals others than radioactive iodine for radiometabolic treatment in thyroid cancer including Peptide Receptor Radionuclides Therapy, alpha emitters and PSMA.

Summary
The standard treatment of differentiated thyroid cancer is radioactive iodine (RAI) but almost half of the metastatic patients become refractory to RAI. New insights in the molecular pathways involved in thyroid cancer and the research of new targets for radionuclide therapy are needed. The awareness on the perspectives both in pre-clinical and in clinical research of alternative radionuclide therapy as well the development of new radiopharmaceuticals with theragnostic purpose are mandatory.

Key Words
Differentiated thyroid cancer, molecular basis, new targets, theragnostic